Christopher Gibson, an officer and director at Recursion Pharmaceuticals, Inc., is set to sell 20,000 Class A shares of the company on 09/05/2024, as per the latest filing. These shares, initially acquired on 09/01/2016 as founders shares in compensation for services, are valued at an aggregate market value of $122,800. This planned transaction follows a series of sales over the past three months, where Gibson sold a total of 270,000 shares, generating gross proceeds of $2,082,300. The notice of the upcoming sale was filed on the same date as the planned sale, with the instruction for this transaction given on 12/27/2023.

Christopher Gibson, an officer and director at Recursion Pharmaceuticals, Inc., is set to sell 20,000 Class A shares of the company on 09/05/2024, as per the latest filing. These shares, initially acquired on 09/01/2016 as founders shares in compensation for services, are valued at an aggregate market value of $122,800. This planned transaction follows a series of sales over the past three months, where Gibson sold a total of 270,000 shares, generating gross proceeds of $2,082,300. The notice of the upcoming sale was filed on the same date as the planned sale, with the instruction for this transaction given on 12/27/2023.